FerringUSA.com | Contact Us
Self-Assessment     Talking With Your Doctor    Useful Links     Ordering     Reimbursement     Newsroom     About Ferring

In this section, you'll find the latest news about EUFLEXXA™ as well as other reports related to the product from Ferring Pharmaceuticals.

4/18/2008
FERRING PHARMACEUTICALS’ EUFLEXXA™ TO SERVE AS SPONSOR FOR SPRINT FORCE AMERICA MASTERS TRACK CLUB

3/17/2008
EUFLEXXA™ CONVERTS TO LATEX-FREE SYRINGE

1/28/2008
FERRING PHARMACEUTICALS ANNOUNCES EUFLEXXA™ AS TITLE SPONSOR OF THE NATIONAL SENIOR GAMES HOCKEY CHAMPIONSHIPS AND THE GEEZERJOCK OF THE YEAR AWARD

1/22/2008
FERRING PHARMACEUTICALS STATEMENT REGARDING RECENT AHRQ REVIEW

12/10/2007
STUDIES SHOW EFFECTIVENESS OF EUFLEXXA™ IN TREATING KNEE OSTEOARTHRITIS AND REDUCING THE PAIN THAT INTERFERES WITH DAILY ACTIVITIES

11/07/2007
COST-EFFECTIVENESS STUDY SUPPORTS USE OF EUFLEXXA™ BY RHEUMATOLOGISTS FOR PAIN RELIEF IN PATIENTS WITH KNEE OSTEOARTHRITIS

8/23/2007
NEW FERRING-COMMISSIONED REPORT ON TRENDS IN MANAGED CARE COVERAGE OF OSTEOARTHRITIS AVAILABLE AT NO CHARGE

8/7/2007
FERRING PHARMACEUTICALS' EUFLEXXA™ SIGNS ON AS A SPONSOR OF THE HUNTSMAN WORLD SENIOR GAMES

1/22/2007
FERRING PHARMACEUTICALS’ EUFLEXXA™ SIGNS ON AS A MAJOR SPONSOR OF THE SENIOR OLYMPICS

4/10/2006
FERRING PHARMACEUTICALS ANNOUNCES EUFLEXXA™ LABELING EXTENDED TO INCLUDE ROOM TEMPERATURE STORAGE

2/14/2006
FERRING PHARMACEUTICALS ANNOUNCES BRUCE JENNER AS NATIONAL SPOKESPERSON FOR EUFLEXXA™

2/14/2006
HEAD-TO-HEAD STUDY SHOWS EUFLEXXA™ HAS GREATER TOLERABILITY COMPARED TO SYNVISC® FOR OSTEOARTHRITIS KNEE PAIN

11/14/2005
FERRING PHARMACEUTICALS ANNOUNCES LAUNCH OF EUFLEXXA™ FOR OSTEOARTHRITIS KNEE PAIN

Privacy Policy | Legal Disclaimer

Click here to receive announcements and additional information about EUFLEXXA.
Click here to request press materials.
Important Treatment Considerations

EUFLEXXA™ (1% sodium hyaluronate) is indicated for the treatment of knee pain due to osteoarthritis (OA). It is used in people who have failed to get adequate pain relief either from simple pain medications, such as acetaminophen, or from exercise and/or physical therapy.

EUFLEXXA should not be used in people who have had any previous allergic reaction to hyaluronate preparations or who have knee joint infections or skin diseases in the area of the injection site.

In a randomized, double-blind, multicenter clinical trial, the only adverse event reported with EUFLEXXA at an incidence greater than 5% was arthralgia (joint pain) (8.75%). Temporary knee pain and swelling may occur after injection with EUFLEXXA.

The safety and effectiveness of injecting EUFLEXXA into the knee together with other injectable medications or into joints other than the knee have not been studied. The safety and effectiveness of treatment cycles of fewer than 3 injections or of repeated treatment cycles with EUFLEXXA have not been established. Strict aseptic technique must be followed to avoid joint infection.

Prescribing Information for Physicians
Important Information for People With OA of the Knee